FDA advisers recommmend CV trial for Vascepa (Amarin)
Amarin Corporation had submitted a Supplemental New Drug Application (sNDA) with the FDA seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for additional use as an adjunct to diet in the treatment of adult patients with high triglycerides and with Mixed Dyslipidemia (ANCHOR indication).
A panel of advisers to the FDA on 16 October condidered that Amarin should be required to complete its ongoing cardiovascular outcomes trial (REDUCE-IT) before the FDA permits the company to expand the labeling for Vascepa.
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
The Menarini Group and Radius Health announced positive topline results from the phase III EMERALD study evaluating RAD 1901 (elacestrant) as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC).
Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.